OncoMatch/Clinical Trials/NCT07438847
177Lu-CTR-FAPI for the Treatment of Thyroid Cancer
Is NCT07438847 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies 177Lu-CTR-FAPI therapy for thyroid cancer.
Treatment: 177Lu-CTR-FAPI therapy — This is a multi-center, open-label, single-arm, dose-escalation phase I study, aiming to evaluate the safety and efficacy of 177Lu-CTR-FAPI (covalent targeted radioligand-fibroblast activation protein inhibitor), a novel radiopharmaceutical in the treatment of thyroid cancer. The primary endpoint of the study is the safety of 177Lu-CTR-FAPI, and the secondary endpoints include treatment response and dosimetry evaluation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Radioligand therapy
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: therapeutic radionuclide therapy
Exception: 131i
Lab requirements
Blood counts
Insufficient major organ function [excluded]
Kidney function
Insufficient major organ function [excluded]
Liver function
Insufficient major organ function [excluded]
Insufficient major organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07438847 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior therapeutic radionuclide therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify